Latest Public Health News

AXP Energy has launched a 1-for-1 non-renounceable entitlement offer seeking between A$1.2 million and A$2.249 million. The funding could support Oklahoma development, but the prospectus also highlights material going-concern uncertainty, creditor dependence and significant dilution for shareholders who do not participate.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

Alcidion delivered a record Q4 FY26 operating cashflow of $7.7 million and secured a $35 million UK contract, while completing a strategic acquisition that expands its ANZ footprint.

Island Pharmaceuticals is progressing its broad-spectrum antiviral Galidesivir amid a severe Ebola outbreak, securing government approvals in Uganda and outlining a dual clinical and regulatory development pathway targeting multiple deadly filoviruses.

Algorae Pharmaceuticals has been appointed as a supplier under a NSW Health public hospital supply contract, marking a strategic milestone despite uncertain immediate revenue impact.

Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.

TruScreen Group posted a NZ$2.25 million loss for FY2026, with its auditor highlighting material uncertainty over the company’s ability to continue without further funding. Revenue rose to NZ$2.4 million amid geographic expansion, but cash burn and accumulated losses remain significant.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.

Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

TruScreen Group reported a 42% increase in FY2026 sales driven by new market entries including India and Indonesia, alongside launching a large-scale cervical cancer screening program in Vietnam and submitting major UNITAID proposals.